Skip to main content

Advertisement

SpringerLink
Log in

Risk factors and outcomes of immune and non-immune causes of diffuse alveolar hemorrhage: a tertiary-care academic single-center experience

  • Observational Research
  • Published:
Rheumatology International Aims and scope Submit manuscript

A Correction to this article was published on 26 April 2021

This article has been updated

Abstract

Diffuse alveolar hemorrhage (DAH) is a rare but potentially life-threatening emergency that has both immune and non-immune etiologies. The objective of this investigation was to compare the risk factors and outcomes of immune and non-immune causes of DAH at a tertiary-care academic center. This was a retrospective observational study conducted at a University center. We reviewed all chest radiographs spanning 12 years (2007–2019) at our institute with the words “diffuse alveolar hemorrhage” in the body of their report, and ascertained cases of DAH through a detailed chart review. We used Chi-squared test to determine the differences in risk factors and outcomes between immune versus non-immune causes of DAH. We performed logistic regressions to assess whether baseline demographics and clinical features influence four critical outcomes: death, shock, renal failure, and severe anemia requiring transfusions. Over the 12-year period, there were 88 patients with DAH, 55 with non-immune and 33 with immune etiologies. Among immune causes of DAH, granulomatosis with polyangiitis (GPA) (10.2%), microscopic polyangiitis (MPA) (9%) and systemic lupus erythematosus (SLE) (9%) were most common. Among non-immune causes of DAH, coagulopathy (6.8%), decompensated heart failure (4.5%) and infection (3.4%) were most common. Patients with non-immune causes of DAH were 45.8% more likely to die and 20.7% less likely to experience sustained remission (p = 0.001). Patient with immune causes of DAH were 21% more likely to have extra-pulmonary findings and 23.7% more likely to have received hemodialysis (HD). The presence of extra-pulmonary findings was statistically significantly correlated with the number of blood products received, the need for HD and non-statistically significantly correlated with likelihood of death. Patients with immune causes of DAH were 71.5% more likely to receive multimodal therapy including corticosteroids. Immune-mediated DAH is associated with a better prognosis than non-immune DAH, despite its greater association with extra-pulmonary findings and requirement for hemodialysis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Change history

References

  1. Park MS (2013) Diffuse alveolar hemorrhage. TubercRespir Dis (Seoul) 74(4):151–162. https://doi.org/10.4046/trd.2013.74.4.151

    Article  Google Scholar 

  2. Nasser M, Cottin V (2018) Alveolar hemorrhage in vasculitis (primary and secondary). SeminRespirCrit Care Med 39(4):482–493. https://doi.org/10.1055/s-0038-1668533

    Article  Google Scholar 

  3. Lara AR, Schwarz MI (2010) Diffuse alveolar hemorrhage. Chest 137(5):1164–1171. https://doi.org/10.1378/chest.08-2084 (PMID: 20442117)

    Article  PubMed  Google Scholar 

  4. Travis WD, Colby TV, Lombard C, Carpenter HA (1990) A clinicopathologic study of 34 cases of diffuse pulmonary hemorrhage with lung biopsy confirmation. Am J SurgPathol 14(12):1112–1125. https://doi.org/10.1097/00000478-199012000-00003

    Article  CAS  Google Scholar 

  5. Kwok SK, Moon SJ, Ju JH, Park KS, Kim WU, Cho CS, Kim HY, Park SH (2011) Diffuse alveolar hemorrhage in systemic lupus erythematosus: risk factors and clinical outcome: results from affiliated hospitals of Catholic University of Korea. Lupus 20(1):102–107. https://doi.org/10.1177/0961203310381511

    Article  PubMed  Google Scholar 

  6. Araujo DB, Borba EF, Silva CA, Campos LMA, Pereira RMR, Bonfa E et al (2012) Alveolar hemorrhage: distinct features of juvenile and adult onset systemic lupus erythematosus. Lupus 21:872–877

    Article  CAS  Google Scholar 

  7. de Prost N, Parrot A, Cuquemelle E, Picard C, Antoine M, Fleury-Feith J, Mayaud C, Boffa JJ, Fartoukh M, Cadranel J (2012) Diffuse alveolar hemorrhage in immunocompetent patients: etiologies and prognosis revisited. Respir Med 106(7):1021–1032. https://doi.org/10.1016/j.rmed.2012.03.015

    Article  PubMed  Google Scholar 

  8. Rajagopala S, Parameswaran S, Ajmera JS, Ganesh RN, Katrevula A (2017) Diffuse alveolar hemorrhage in IgA nephropathy: case series and systematic review of the literature. Int J Rheum Dis 20(1):109–121. https://doi.org/10.1111/1756-185X.12818

    Article  CAS  PubMed  Google Scholar 

  9. Dugo M, Pasi A, Gatti PL, Mastrosimone S, Laurino L, Barberio G, Farneti F, Facchini C, Maresca MC (2014) La Malattia di Goodpasture: l'esperienza di un singolo centro [Goodpasture's disease: a case series]. Ital Nefro 31(1).

  10. Picard C, Cadranel J, Porcher R, Prigent H, Levy P, Fartoukh M, Mayaud C, Parrot A (2010) Alveolar haemorrhage in the immunocompetent host: a scale for early diagnosis of an immune cause. Respiration 80(4):313–320. https://doi.org/10.1159/000315144

    Article  PubMed  Google Scholar 

  11. Hunder GG, Arend WP, Bloch DA, Calabrese LH, Fauci AS, Fries JF, Leavitt RY, Lie JT, Lightfoot RW Jr, Masi AT et al (1990) The American College of Rheumatology 1990 criteria for the classification of vasculitis. Arthritis Rheum 33(8):1065–1067. https://doi.org/10.1002/art.1780330802

    Article  CAS  PubMed  Google Scholar 

  12. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR (2019) 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 71(9):1400–1412. https://doi.org/10.1002/art.40930

    Article  PubMed  PubMed Central  Google Scholar 

  13. Rabe C, Appenrodt B, Hoff C, Ewig S, Klehr HU, Sauerbruch T, Nickenig G, Tasci S (2010) Severe respiratory failure due to diffuse alveolar hemorrhage: clinical characteristics and outcome of intensive care. J Crit Care 25(2):230–235. https://doi.org/10.1016/j.jcrc.2009.04.009

    Article  PubMed  Google Scholar 

  14. Zamora MR, Warner ML, Tuder R, Schwarz MI (1997) Diffuse alveolar hemorrhage and systemic lupus erythematosus, clinical presentation, histology, survival, and outcome. Medicine (Baltimore) 76(3):192–202. https://doi.org/10.1097/00005792-199705000-00005 (PMID: 9193454)

    Article  CAS  Google Scholar 

  15. Specks U (2001) Diffuse alveolar hemorrhage syndromes. CurrOpinRheumatol 13(1):12–17. https://doi.org/10.1097/00002281-200101000-00003

    Article  CAS  Google Scholar 

  16. Rathi NK, Tanner AR, Dinh A, Dong W, Feng L, Ensor J, Wallace SK, Haque SA, Rondon G, Price KJ, Popat U, Nates J (2015) Low-, medium- and high-dose steroids with or without aminocaproic acid in adult hematopoietic SCT patients with diffuse alveolar hemorrhage. Bone Marrow Transplant 50(3):420–426. https://doi.org/10.1038/bmt.2014.287

    Article  CAS  PubMed  Google Scholar 

  17. Walsh M, Merkel PA, Peh CA, Szpirt WM, Puéchal X, Fujimoto S, Hawley CM, Khalidi N, Floßmann O, Wald R, Girard LP, Levin A, Gregorini G, Harper L, Clark WF, Pagnoux C, Specks U, Smyth L, Tesar V, Ito-Ihara T, de Zoysa JR, Szczeklik W, Flores-Suárez LF, Carette S, Guillevin L, Pusey CD, Casian AL, Brezina B, Mazzetti A, McAlear CA, Broadhurst E, Reidlinger D, Mehta S, Ives N, Jayne DRW, PEXIVAS Investigators (2020) Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 382(7):622–631

    Article  CAS  Google Scholar 

  18. Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St. Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363(3):221–232. https://doi.org/10.1056/NEJMoa0909905

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Lin Y, Zheng W, Tian X, Zhang X, Zhang F, Dong Y (2009) Antineutrophil cytoplasmic antibody-associated vasculitis complicated with diffuse alveolar hemorrhage: a study of 12 cases. J ClinRheumatol 15(7):341–344. https://doi.org/10.1097/RHU.0b013e3181b59581

    Article  Google Scholar 

Download references

Funding

There are no sources of funding for this investigation.

Author information

Authors and Affiliations

  1. Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR, 97239, USA

    A. Bhushan, D. Choi, G. Maresh & A. Deodhar

  2. Graduate School of Dentistry, Kyung Hee University, Seoul, Korea

    D. Choi

Authors
  1. A. Bhushan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Maresh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Deodhar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Bhushan.

Ethics declarations

Conflict of interest

A Deodhar has the following conflicts: Research Grants: AbbVie, Eli Lilly, GSK, Novartis, Pfizer, UCB. Consultant or Advisory Boards: Amgen, AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, GSK, Janssen, Novartis, Pfizer, UCB. The other authors have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original online version of this article was revised due to incorrect affiliation of the second author.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bhushan, A., Choi, D., Maresh, G. et al. Risk factors and outcomes of immune and non-immune causes of diffuse alveolar hemorrhage: a tertiary-care academic single-center experience. Rheumatol Int 42, 485–492 (2022). https://doi.org/10.1007/s00296-021-04842-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-021-04842-2

Search

Navigation